Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022Business Wire • 11/03/22
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks VideoPRNewsWire • 10/18/22
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness Wire • 10/11/22
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockBusiness Wire • 10/07/22
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALSBusiness Wire • 09/29/22
IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long BattleInvestors Business Daily • 09/29/22
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and DiscoveriesBusiness Wire • 09/14/22
Andreas Halvorsen Curbs Amylyx Pharmaceuticals Stake After ALS Drug Gets Committee's ApprovalGuruFocus • 09/13/22
This Stock Has Delivered a Gain of 100% Over the Past 3 Months. Can You Still Buy?The Motley Fool • 09/12/22
Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual CompoundsBusiness Wire • 09/12/22
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALSBusiness Wire • 09/07/22